Clinical trial
Anidulafungin in Treating Immunocompromised Children With Neutropenia
NCT00068471 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00068471 |
|---|---|
| Title | Anidulafungin in Treating Immunocompromised Children With Neutropenia |
| Official title | Phase I-II Study of the Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children With Neutropenia |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Infection, Neutropenia, Unspecified Childhood Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | anidulafungin |
| Start date | Jul 1, 2003 |
| Completion | Oct 1, 2007 |
| First posted | Sep 11, 2003 |
| Last update posted | Jun 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: